Novel PET Agent Effectively Detects Multiple Cancers, Identifies Patients for Targeted Therapies

@JournalofNucMed, November 12, 2022

A new molecular Imaging radiotracer can precisely diagnose a variety of cancers, providing a roadmap to identify patients who may benefit from targeted Radionuclide therapies. ” These results suggest clinical scenarios in which 68Ga-PentixaFor PET may prove beneficial for directing CXCR4-targeted therapies,” said [Prof. Dr. Andreas] Buck. “This is of particular importance for malignancies that lack a more suitable Imaging modality. A pivotal phase III study is planned to continue this research in the second quarter of 2023.”

>> Read the article